Foreign institutional investors (FIIs) shifted their focus from index-constituent pharmaceutical stocks to mid-cap counters in the July-September quarter.
The FIIs are estimated to have purchased Rs 1,000 crore worth of equity in mid-cap companies during the quarter, according to shareholding data released by companies to the Bombay Stock Exchange (BSE).
FIIs purchased 12.12 million shares of second-line stocks such as Cadila Healthcare, Glenmark Pharmaceuticals, Ipca Laboratories, Lupin and Shasun Chemicals.
